$MEIP
MEI Pharma, Inc.

2015 Q3 Form 10-Q Financial Statement

#000119312515369234 Filed on November 06, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2014 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.830M $2.440M
YoY Change -25.0% 34.81%
% of Gross Profit
Research & Development $2.816M $6.566M
YoY Change -57.11% 111.67%
% of Gross Profit
Depreciation & Amortization $15.00K $16.00K
YoY Change -6.25% 23.08%
% of Gross Profit
Operating Expenses $4.646M $9.005M
YoY Change -48.41% 83.29%
Operating Profit -$4.646M -$9.005M
YoY Change -48.41% 83.29%
Interest Expense $30.00K $10.00K
YoY Change 200.0% -50.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$4.620M -$8.990M
YoY Change -48.61% 83.47%
Income Tax $1.000K $0.00
% Of Pretax Income
Net Earnings -$4.620M -$8.993M
YoY Change -48.63% 83.68%
Net Earnings / Revenue
Basic Earnings Per Share -$0.13
Diluted Earnings Per Share -$0.13 -$415.2K
COMMON SHARES
Basic Shares Outstanding 34.16M shares 21.61M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q3 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $58.00M $42.10M
YoY Change 37.77% 33.65%
Cash & Equivalents $17.88M $17.04M
Short-Term Investments $40.10M $25.00M
Other Short-Term Assets $600.0K $400.0K
YoY Change 50.0% -33.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $58.61M $42.42M
YoY Change 38.19% 32.11%
LONG-TERM ASSETS
Property, Plant & Equipment $62.00K $75.00K
YoY Change -17.33% 50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $454.0K $502.0K
YoY Change -9.56% -1.76%
TOTAL ASSETS
Total Short-Term Assets $58.61M $42.42M
Total Long-Term Assets $454.0K $502.0K
Total Assets $59.07M $42.92M
YoY Change 37.63% 31.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $253.0K $1.111M
YoY Change -77.23% 99.46%
Accrued Expenses $2.874M $4.197M
YoY Change -31.52% 362.22%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.127M $5.308M
YoY Change -41.09% 262.32%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.127M $5.308M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $3.100M $5.300M
YoY Change -41.51% 253.33%
SHAREHOLDERS EQUITY
Retained Earnings -$160.8M -$132.4M
YoY Change 21.38% 30.88%
Common Stock $216.7M $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $55.94M $37.61M
YoY Change
Total Liabilities & Shareholders Equity $59.07M $42.92M
YoY Change 37.63% 31.58%

Cashflow Statement

Concept 2015 Q3 2014 Q3
OPERATING ACTIVITIES
Net Income -$4.620M -$8.993M
YoY Change -48.63% 83.68%
Depreciation, Depletion And Amortization $15.00K $16.00K
YoY Change -6.25% 23.08%
Cash From Operating Activities -$5.760M -$6.730M
YoY Change -14.41% 65.64%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $4.920M $10.00M
YoY Change -50.8%
Cash From Investing Activities $4.920M $10.00M
YoY Change -50.8% -166766.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -5.760M -6.730M
Cash From Investing Activities 4.920M 10.00M
Cash From Financing Activities
Net Change In Cash -840.0K 3.270M
YoY Change -125.69% -180.36%
FREE CASH FLOW
Cash From Operating Activities -$5.760M -$6.730M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q2 meip Public Float Maximum Value
PublicFloatMaximumValue
75000000
CY2015Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-160759000
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
55941000
CY2015Q3 us-gaap Short Term Investments
ShortTermInvestments
40142000
CY2015Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
59068000
CY2015Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
253000
CY2015Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
34155997 shares
CY2012Q3 meip Milestone Payments Maximum Amount
MilestonePaymentsMaximumAmount
75200000
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17041000
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2648937 shares
CY2015Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.84
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
113000000 shares
CY2015Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34155997 shares
CY2015Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
815872 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.67
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34155997 shares
CY2015Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2015Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3127000
CY2015Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2874000
CY2015Q3 us-gaap Common Stock Value
CommonStockValue
0
CY2015Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
216700000
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
242000
CY2015Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
58018000
CY2015Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
62000
CY2015Q3 us-gaap Assets Current
AssetsCurrent
58614000
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2015Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
392000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17876000
CY2015Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2015Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2800000
CY2015Q3 us-gaap Assets
Assets
59068000
CY2015Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
596000
CY2015Q3 meip Shelf Registration Statement Value
ShelfRegistrationStatementValue
104000000
CY2015Q3 meip Accrued Milestone Payments
AccruedMilestonePayments
100000
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13777000
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1614317 shares
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
113000000 shares
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34155997 shares
CY2015Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.07
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34155997 shares
CY2015Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2015Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4959000
CY2015Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4096000
CY2015Q2 us-gaap Common Stock Value
CommonStockValue
0
CY2015Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
215930000
CY2015Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-156139000
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
59791000
CY2015Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
64750000
CY2015Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
863000
CY2015Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
63779000
CY2015Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
68000
CY2015Q2 us-gaap Assets Current
AssetsCurrent
64281000
CY2015Q2 us-gaap Short Term Investments
ShortTermInvestments
45057000
CY2015Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
401000
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18722000
CY2015Q2 us-gaap Assets
Assets
64750000
CY2015Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
502000
CY2012Q3 us-gaap Stock Issued During Period Shares Purchase Of Assets
StockIssuedDuringPeriodSharesPurchaseOfAssets
195756 shares
CY2012Q3 us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
500000
CY2012Q3 meip Upfront And Milestone Payments
UpfrontAndMilestonePayments
200000
CY2012Q3 meip Percentage Of Purchases From Major Suppliers
PercentageOfPurchasesFromMajorSuppliers
1.00 pure
CY2012Q3 meip Agreement Termination Notice Period
AgreementTerminationNoticePeriod
P90D
CY2014Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2014Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6845761 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.017 pure
CY2014Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0 shares
CY2014Q3 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6731000
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.42
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.15
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21652223 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.170 pure
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2014Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
12000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9005000
CY2014Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-144000
CY2014Q3 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
4998000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-8993000
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
9005000
CY2014Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
16000
CY2015Q3 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2015Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6543678 shares
CY2014Q3 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
14993000
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2439000
CY2014Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3264000
CY2014Q3 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-597000
CY2014Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1410000
CY2014Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1289000
CY2014Q3 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
9995000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6566000
CY2015Q3 dei Document Type
DocumentType
10-Q
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
13705 shares
CY2015Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y8M12D
CY2015Q3 dei Trading Symbol
TradingSymbol
MEIP
CY2015Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001262104
CY2015Q3 dei Document Period End Date
DocumentPeriodEndDate
2015-09-30
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
137637 shares
CY2015Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2015Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y6M
CY2015Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.62
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.018 pure
CY2015Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0 shares
CY2015Q3 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-5761000
CY2015Q3 dei Amendment Flag
AmendmentFlag
false
CY2015Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.55
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.38
CY2015Q3 dei Entity Registrant Name
EntityRegistrantName
MEI Pharma, Inc.
CY2015Q3 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. The Company uses estimates that affect the reported amounts (including assets, liabilities, revenues and expenses) and related disclosures. Actual results could materially differ from those estimates.</p> </div>
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34334257 shares
CY2015Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y2M12D
CY2015Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2015Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
94000
CY2015Q3 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
20125000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-4620000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
4646000
CY2015Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
15000
CY2015Q3 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
4915000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2816000
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.174 pure
CY2015Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
4.62
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1185962 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2015Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y4M24D
CY2015Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
27000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4646000
CY2015Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2015Q3 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
25040000
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1830000
CY2015Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-846000
CY2015Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
27000
CY2015Q3 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-610000
CY2015Q3 us-gaap Share Based Compensation
ShareBasedCompensation
770000
CY2015Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1222000
CY2015Q3 meip Lease Expiration Month And Year
LeaseExpirationMonthAndYear
2016-06
CY2015Q3 meip Lease Arrangement Rent Area
LeaseArrangementRentArea
8800 sqft

Files In Submission

Name View Source Status
0001193125-15-369234-index-headers.html Edgar Link pending
0001193125-15-369234-index.html Edgar Link pending
0001193125-15-369234.txt Edgar Link pending
0001193125-15-369234-xbrl.zip Edgar Link pending
d71519d10q.htm Edgar Link pending
d71519dex311.htm Edgar Link pending
d71519dex312.htm Edgar Link pending
d71519dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
meip-20150930.xml Edgar Link completed
meip-20150930.xsd Edgar Link pending
meip-20150930_cal.xml Edgar Link unprocessable
meip-20150930_def.xml Edgar Link unprocessable
meip-20150930_lab.xml Edgar Link unprocessable
meip-20150930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending